| Specificity |
The product is specific for Bevacizumab. This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays. |
| Host Species |
Rabbit |
| Immunogen |
Bevacizumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.05-0.2 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Antigen affinity purification |
| Isotype |
Rabbit IgG |
| Clonality |
Polyclonal |
| Clone ID |
Not applicable |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
Anti-Bevacizumab Antibody, pAb, Rabbit (GenScript, A01887-40) binds with Bevacizumab.
Dilution: Start from 1,000 ng/ml. EC50= 13.26 ng/ml.
Coating antigen: Bevacizumab. 1 µg/ml.
Anti-Bevacizumab Antibody, pAb, Rabbit (GenScript, A01887-40) binds with Bevacizumab.
Dilution: Start from 1,000 ng/ml. EC50= 13.26 ng/ml.
Coating antigen: Bevacizumab. 1 µg/ml.
Anti-Bevacizumab Antibody, pAb, Rabbit (GenScript, A01887-40) binds with Bevacizumab.
Dilution: Start from 1,000 ng/ml. EC50= 13.26 ng/ml.
Coating antigen: Bevacizumab. 1 µg/ml.
| Target Background |
Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).GenScript Anti-Bevacizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Bevacizumab. |
| Synonyms |
Rabbit polyclonal to Avastin |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
